Table 2.

Summary risk ratios (RRs) for the association of breast, endometrial, and ovarian cancer risk with acrylamide intake comparing the highest versus the lowest exposure categories for overall study population and restricted to never-smoking women.

All womenNever-smoking women
nRR (95% CI)I2 (%)nRR (95% CI)I2 (%)
Breast cancer
All studies80.96 (0.91–1.02)0.060.92 (0.84–1.00)0.0
Menopausal status
 Premenopausal41.02 (0.85–1.21)38.511.17 (0.69–2.00)
 Postmenopausal50.93 (0.87–1.00)0.031.02 (0.85–1.23)0.0
BMI
 <25 kg/m220.93 (0.83–1.03)0.0
 ≥25 kg/m220.97 (0.87–1.08)0.0
Hormone receptor status
 ER+30.90 (0.74–1.10)0.011.31 (0.87–1.97)
 ER20.87 (0.60–1.27)0.010.95 (0.52–1.72)
 PR+21.02 (0.77–1.36)0.011.47 (0.86–2.51)
 PR20.84 (0.61–1.16)0.010.84 (0.63–1.56)
 ER+PR+50.98 (0.89–1.08)0.011.43 (0.83–2.46)
 ERPR50.89 (0.78–1.02)0.0
 ER+PR21.09 (0.89–1.33)0.0
 ERPR+11.09 (0.63–1.88)
Endometrial cancer
All studies61.03 (0.91–1.17)0.061.14 (0.96–1.36)0.0
Menopausal status
 Premenopausal50.89 (0.62–1.29)43.4
 Postmenopausal51.05 (0.88–1.25)0.021.31 (0.95–1.82)0.0
BMI
 <25 kg/m241.25 (0.73–2.13)73.4
 ≥25 kg/m240.98 (0.76–1.25)12.6
Ovarian cancer
All studies61.01 (0.87–1.18)25.941.17 (0.79–1.72)49.5
Menopausal status
 Premenopausal21.15 (0.51–2.60)41.2
 Postmenopausal41.05 (0.82–1.33)33.221.41 (0.75–2.63)56.8
BMI
 <25 kg/m221.25 (0.57–2.73)78.0
 ≥25 kg/m220.78 (0.49–1.24)0.0
  • Abbreviations: BMI, body mass index; ER, estrogen receptor; I2 (%), heterogeneity; n, number of studies; PR, progesterone receptor.